Antisense Therapeutics

Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.